Evaluating the Progression of Large Language Model Capabilities for Small-Molecule Drug Design

arXiv cs.LG / 4/20/2026

📰 NewsSignals & Early TrendsIdeas & Deep AnalysisModels & Research

Key Points

  • The paper argues that large language models could accelerate small-molecule drug design but notes that their real-world utility is unclear due to insufficient benchmarks.
  • It introduces a benchmark suite of chemically grounded tasks—covering property prediction, molecular representation transformations, and molecular design—and formulates them as reinforcement learning (RL) environments for consistent evaluation.
  • Experiments across three model families show that frontier LLMs perform better on chemical tasks, yet they still leave substantial gaps, especially when experimental settings have low data.
  • The authors demonstrate that RL-based post-training can significantly boost performance, enabling a smaller post-trained model to approach state-of-the-art frontier models despite starting from a weaker base model.

Abstract

Large Language Models (LLMs) have the potential to accelerate small molecule drug design due to their ability to reason about information from diverse sources and formats. However, their practical utility remains unclear due to the lack of benchmarks that reflect real-world scenarios. In this work, we introduce a suite of chemically-grounded tasks spanning molecular property prediction, molecular representation transformations, and molecular design. Importantly, we formulate these tasks as reinforcement learning (RL) environments, enabling a unified approach for evaluation and post-training. Across three model families, we find that frontier models are increasingly proficient at chemical tasks, but that there is significant room for improvement, especially in experimental settings with low data. Critically, we show that RL-based post-training can substantially improve performance. A smaller model post-trained on our environments becomes competitive with state-of-the-art frontier models, despite a significantly weaker base model. This suggests a practical route toward employing LLMs in drug discovery; by combining carefully-designed evaluation tasks with targeted post-training, we can both elucidate and close critical capability gaps.